Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 188


Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.

Bhatia A, Ulaner G, Rampal R, Hyman DM, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Lacouture ME, Hajdenberg J, Ganzel C, Diamond EL.

Haematologica. 2018 Feb 22. pii: haematol.2017.185298. doi: 10.3324/haematol.2017.185298. [Epub ahead of print] No abstract available.


The microbial flora of taxane therapy-associated nail disease in cancer patients.

Virgen CA, Belum VR, Kamboj M, Goldfarb SB, Blinder VS, Gucalp A, Lacouture ME.

J Am Acad Dermatol. 2018 Mar;78(3):607-609. doi: 10.1016/j.jaad.2017.08.038. No abstract available.


SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.

White KD, Abe R, Ardern-Jones M, Beachkofsky T, Bouchard C, Carleton B, Chodosh J, Cibotti R, Davis R, Denny JC, Dodiuk-Gad RP, Ergen EN, Goldman JL, Holmes JH 4th, Hung SI, Lacouture ME, Lehloenya RJ, Mallal S, Manolio TA, Micheletti RG, Mitchell CM, Mockenhaupt M, Ostrov DA, Pavlos R, Pirmohamed M, Pope E, Redwood A, Rosenbach M, Rosenblum MD, Roujeau JC, Saavedra AP, Saeed HN, Struewing JP, Sueki H, Sukasem C, Sung C, Trubiano JA, Weintraub J, Wheatley LM, Williams KB, Worley B, Chung WH, Shear NH, Phillips EJ.

J Allergy Clin Immunol Pract. 2018 Jan - Feb;6(1):38-69. doi: 10.1016/j.jaip.2017.11.023. Review.


Inflammatory dermatoses, infections, and drug eruptions are the most common skin conditions in hospitalized cancer patients.

Phillips GS, Freites-Martinez A, Hsu M, Skripnik Lucas A, Barrios DM, Ciccolini K, Marchetti MA, Deng L, Myskowski PL, Lee EH, Markova A, Lacouture ME.

J Am Acad Dermatol. 2017 Dec 19. pii: S0190-9622(17)32869-4. doi: 10.1016/j.jaad.2017.12.031. [Epub ahead of print]


Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.

Geller S, Xu H, Lebwohl M, Nardone B, Lacouture ME, Kheterpal M.

Am J Clin Dermatol. 2017 Dec 19. doi: 10.1007/s40257-017-0337-2. [Epub ahead of print] Review.


First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT.

Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15.


Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group.

J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z.


A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies.

Tischer B, Bilang M, Kraemer M, Ronga P, Lacouture ME.

Support Care Cancer. 2018 Apr;26(4):1169-1179. doi: 10.1007/s00520-017-3938-7. Epub 2017 Nov 7.


Granuloma annulare associated with immune checkpoint inhibitors.

Wu J, Kwong BY, Martires KJ, Rieger KE, Chung WH, Iyer GV, Lacouture ME.

J Eur Acad Dermatol Venereol. 2017 Oct 6. doi: 10.1111/jdv.14617. [Epub ahead of print] No abstract available.


Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia: a review of controlled clinical trials.

Shah VV, Wikramanayake TC, DelCanto GM, van den Hurk C, Wu S, Lacouture ME, Jimenez JJ.

J Eur Acad Dermatol Venereol. 2017 Oct 4. doi: 10.1111/jdv.14612. [Epub ahead of print] Review.


Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.

Dai J, Belum VR, Wu S, Sibaud V, Lacouture ME.

J Am Acad Dermatol. 2017 Nov;77(5):902-910.e2. doi: 10.1016/j.jaad.2017.06.044. Epub 2017 Sep 14. Review.


Olmutinib-induced palmoplantar keratoderma.

Chen KL, Cho YT, Yang CW, Sheen YS, Liang CW, Lacouture ME, Chu CY.

Br J Dermatol. 2018 Feb;178(2):e129-e131. doi: 10.1111/bjd.15935. Epub 2017 Dec 18. No abstract available.


Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.

Kaunitz GJ, Loss M, Rizvi H, Ravi S, Cuda JD, Bleich KB, Esandrio J, Sander I, Le DT, Diaz LA Jr, Brahmer JR, Drake CG, Hollmann TJ, Lacouture ME, Hellmann MD, Lipson EJ, Taube JM.

Am J Surg Pathol. 2017 Oct;41(10):1381-1389. doi: 10.1097/PAS.0000000000000900.


A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash.

Belum VR, Marchetti MA, Dusza SW, Cercek A, Kemeny NE, Lacouture ME.

J Am Acad Dermatol. 2017 Sep;77(3):577-579. doi: 10.1016/j.jaad.2017.03.039. No abstract available.


Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis.

Zarnegar S, Durham BH, Khattar P, Shukla NN, Benayed R, Lacouture ME, Lavi E, Lyden DC, Diamond EL, Dunkel IJ, Abdel-Wahab O.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26699. Epub 2017 Jul 27.


Post-reconstruction dermatitis of the breast.

Rosen AC, Goh C, Lacouture ME, Mehrara BJ, Cordeiro PG, Myskowski PL.

J Plast Reconstr Aesthet Surg. 2017 Oct;70(10):1369-1376. doi: 10.1016/j.bjps.2017.05.012. Epub 2017 May 20.


Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy.

Freites-Martinez A, Kwong BY, Rieger KE, Coit DG, Colevas AD, Lacouture ME.

JAMA Dermatol. 2017 Jul 1;153(7):694-697. doi: 10.1001/jamadermatol.2017.0989.


Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings.

Sibaud V, Eid C, Belum VR, Combemale P, Barres B, Lamant L, Mourey L, Gomez-Roca C, Estilo CL, Motzer R, Vigarios E, Lacouture ME.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):e464-e469. doi: 10.1111/jdv.14284. Epub 2017 May 8. No abstract available.


Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).

Kim DW, Garon EB, Jatoi A, Keefe DM, Lacouture ME, Sonis S, Gernhardt D, Wang T, Giri N, Doherty JP, Nadanaciva S, O'Connell J, Sbar E, Cho BC.

Lung Cancer. 2017 Apr;106:76-82. doi: 10.1016/j.lungcan.2017.01.021. Epub 2017 Feb 1.


A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.

Smyth LM, Monson KR, Jhaveri K, Drilon A, Li BT, Abida W, Iyer G, Gerecitano JF, Gounder M, Harding JJ, Voss MH, Makker V, Ho AL, Razavi P, Iasonos A, Bialer P, Lacouture ME, Teitcher JB, Erinjeri JP, Katabi N, Fury MG, Hyman DM.

Invest New Drugs. 2017 Dec;35(6):742-750. doi: 10.1007/s10637-017-0445-0. Epub 2017 Mar 9.


Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors.

Zarbo A, Belum VR, Sibaud V, Oudard S, Postow MA, Hsieh JJ, Motzer RJ, Busam KJ, Lacouture ME.

Br J Dermatol. 2017 Jun;176(6):1649-1652. doi: 10.1111/bjd.15237. Epub 2017 Apr 24.


Development of Papulopustular Rosacea during Nivolumab Therapy for Metastatic Cancer.

Bousquet E, Zarbo A, Tournier E, Chevreau C, Mazieres J, Lacouture ME, Sibaud V.

Acta Derm Venereol. 2017 Apr 6;97(4):539-540. doi: 10.2340/00015555-2566. No abstract available.


A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling.

McArthur HL, Diab A, Page DB, Yuan J, Solomon SB, Sacchini V, Comstock C, Durack JC, Maybody M, Sung J, Ginsberg A, Wong P, Barlas A, Dong Z, Zhao C, Blum B, Patil S, Neville D, Comen EA, Morris EA, Kotin A, Brogi E, Wen YH, Morrow M, Lacouture ME, Sharma P, Allison JP, Hudis CA, Wolchok JD, Norton L.

Clin Cancer Res. 2016 Dec 1;22(23):5729-5737. Epub 2016 Aug 26.


reply to the letter to the editor 'Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial' by Ceccarelli et al.

Lacouture ME; authors of the publication “A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer”.

Ann Oncol. 2016 Nov;27(11):2138-2139. Epub 2016 Sep 23. No abstract available.


Dermatological adverse events with taxane chemotherapy.

Sibaud V, Lebœuf NR, Roche H, Belum VR, Gladieff L, Deslandres M, Montastruc M, Eche A, Vigarios E, Dalenc F, Lacouture ME.

Eur J Dermatol. 2016 Oct 1;26(5):427-443. Review.


Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.

Tischer B, Huber R, Kraemer M, Lacouture ME.

Support Care Cancer. 2017 Feb;25(2):651-660. doi: 10.1007/s00520-016-3419-4. Epub 2016 Oct 7. Review.


Stoma care products represent a common and previously underreported source of peristomal contact dermatitis.

Cressey BD, Belum VR, Scheinman P, Silvestri D, McEntee N, Livingston V, Lacouture ME, Zippin JH.

Contact Dermatitis. 2017 Jan;76(1):27-33. doi: 10.1111/cod.12678. Epub 2016 Aug 31.


Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.

Lacouture ME, Dréno B, Ascierto PA, Dummer R, Basset-Seguin N, Fife K, Ernst S, Licitra L, Neves RI, Peris K, Puig S, Sokolof J, Sekulic A, Hauschild A, Kunstfeld R.

Oncologist. 2016 Oct;21(10):1218-1229. Epub 2016 Aug 10. Review.


Increased Airport Scrutiny by the Transportation Security Administration of a Patient-Passenger Carrying Ammonium Lactate-Containing Moisturizer.

Zarbo A, Ouerfelli O, Klang M, Lacouture ME.

JAMA Dermatol. 2016 Sep 1;152(9):1054-5. doi: 10.1001/jamadermatol.2016.2665. No abstract available.


Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors.

Hofheinz RD, Deplanque G, Komatsu Y, Kobayashi Y, Ocvirk J, Racca P, Guenther S, Zhang J, Lacouture ME, Jatoi A.

Oncologist. 2016 Dec;21(12):1483-1491. Epub 2016 Jul 22. Review.


A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer.

Lacouture ME, Keefe DM, Sonis S, Jatoi A, Gernhardt D, Wang T, Doherty JP, Giri N, Nadanaciva S, O'Connell J, Sbar E, Piperdi B, Garon EB.

Ann Oncol. 2016 Sep;27(9):1712-8. doi: 10.1093/annonc/mdw227. Epub 2016 Jun 10.


Mechanisms of skin aging induced by EGFR inhibitors.

Gerber PA, Buhren BA, Schrumpf H, Hevezi P, Bölke E, Sohn D, Jänicke RU, Belum VR, Robert C, Lacouture ME, Homey B.

Support Care Cancer. 2016 Oct;24(10):4241-8. doi: 10.1007/s00520-016-3254-7. Epub 2016 May 10.


Cold thermal injury from cold caps used for the prevention of chemotherapy-induced alopecia.

Belum VR, de Barros Silva G, Laloni MT, Ciccolini K, Goldfarb SB, Norton L, Sklarin NT, Lacouture ME.

Breast Cancer Res Treat. 2016 Jun;157(2):395-400. doi: 10.1007/s10549-016-3799-7. Epub 2016 May 5.


Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD.

Ann Oncol. 2016 Jul;27(7):1362. doi: 10.1093/annonc/mdw141. Epub 2016 Apr 12. No abstract available.


Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.

Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, Motzer RJ, Wu S, Busam KJ, Wolchok JD, Lacouture ME.

Eur J Cancer. 2016 Jun;60:12-25. doi: 10.1016/j.ejca.2016.02.010. Epub 2016 Apr 1. Review.


Management of Dermatologic Toxicities Associated With Targeted Therapy.

Lacouture ME.

J Adv Pract Oncol. 2016 Apr;7(3):331-334. Epub 2016 Apr 1. Review. No abstract available.


Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.

Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page DB, Postow MA, Weinstein A, Lucas AS, Ciccolini KT, Quigley EA, Lesokhin AM, Paik PK, Chaft JE, Segal NH, D'Angelo SP, Dickson MA, Wolchok JD, Lacouture ME.

Cancer Immunol Res. 2016 May;4(5):383-9. doi: 10.1158/2326-6066.CIR-15-0123. Epub 2016 Feb 29.


Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.

Drilon A, Eaton AA, Schindler K, Gounder MM, Spriggs DR, Harris P, Ivy SP, Iasonos A, Lacouture ME, Hyman DM.

Cancer. 2016 Apr 15;122(8):1228-37. doi: 10.1002/cncr.29918. Epub 2016 Feb 24.


A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.

Iyengar NM, Fornier MN, Sugarman SM, Theodoulou M, Troso-Sandoval TA, D'Andrea GM, Drullinsky PR, Gajria D, Goldfarb SB, Comen EA, Lake DE, Modi S, Traina TA, Lacouture ME, Chen MF, Patil S, Baselga J, Norton L, Hudis CA, Dang CT.

Clin Breast Cancer. 2016 Apr;16(2):87-94. doi: 10.1016/j.clbc.2015.09.009. Epub 2015 Sep 25.


Alopecia in patients treated with molecularly targeted anticancer therapies.

Belum VR, Marulanda K, Ensslin C, Gorcey L, Parikh T, Wu S, Busam KJ, Gerber PA, Lacouture ME.

Ann Oncol. 2015 Dec;26(12):2496-502. doi: 10.1093/annonc/mdv390. Epub 2015 Sep 19.


Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD.

Ann Oncol. 2015 Dec;26(12):2375-91. doi: 10.1093/annonc/mdv383. Epub 2015 Sep 14. Review. Erratum in: Ann Oncol. 2016 Jul;27(7):1362.


Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.

Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, Zaja F, Devlin S, Pulsoni A, Chung YR, Cimminiello M, Kim E, Rossi D, Stone RM, Motta G, Saven A, Varettoni M, Altman JK, Anastasia A, Grever MR, Ambrosetti A, Rai KR, Fraticelli V, Lacouture ME, Carella AM, Levine RL, Leoni P, Rambaldi A, Falzetti F, Ascani S, Capponi M, Martelli MP, Park CY, Pileri SA, Rosen N, Foà R, Berger MF, Zinzani PL, Abdel-Wahab O, Falini B, Tallman MS.

N Engl J Med. 2015 Oct 29;373(18):1733-47. doi: 10.1056/NEJMoa1506583. Epub 2015 Sep 9.


Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center.

Watts JM, Kishtagari A, Hsu M, Lacouture ME, Postow MA, Park JH, Stein EM, Teruya-Feldstein J, Abdel-Wahab O, Devlin SM, Tallman MS.

Br J Haematol. 2015 Oct;171(1):84-90. doi: 10.1111/bjh.13528. Epub 2015 Jun 26.


Xerosis and pruritus as major EGFRI-associated adverse events.

Clabbers JMK, Boers-Doets CB, Gelderblom H, Stijnen T, Lacouture ME, van der Hoeven KJM, Kaptein AA.

Support Care Cancer. 2016 Feb;24(2):513-521. doi: 10.1007/s00520-015-2781-y. Epub 2015 Jun 27.


Histopathologic Features of Cutaneous Acute Graft-Versus-Host Disease in T-Cell-Depleted Peripheral Blood Stem Cell Transplant Recipients.

Fischer A, Jakubowski AA, Lacouture ME, Hollmann TJ, Drucker AM, Maloy M, Prockop S, Querfeld C, Busam KJ, Pulitzer MP.

Am J Dermatopathol. 2015 Jul;37(7):523-9. doi: 10.1097/DAD.0000000000000357.


Reply to: "Skin moisturization for xerosis related to targeted anticancer therapies".

Valentine J, Belum VR, Duran J, Ciccolini K, Schindler K, Wu S, Lacouture ME.

J Am Acad Dermatol. 2015 Jul;73(1):e35-6. doi: 10.1016/j.jaad.2015.03.038. No abstract available.


Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.

McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E.

Ann Oncol. 2015 Oct;26(10):2017-26. doi: 10.1093/annonc/mdv244. Epub 2015 Jun 1. Review.


Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis.

Belum VR, Serna-Tamayo C, Wu S, Lacouture ME.

Clin Exp Dermatol. 2016 Jan;41(1):8-15. doi: 10.1111/ced.12694. Epub 2015 May 25. Review.


Management of dermatologic toxicities.

Lacouture ME.

J Natl Compr Canc Netw. 2015 May;13(5 Suppl):686-9.


A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.

Harding JJ, Catalanotti F, Munhoz RR, Cheng DT, Yaqubie A, Kelly N, McDermott GC, Kersellius R, Merghoub T, Lacouture ME, Carvajal RD, Panageas KS, Berger MF, Rosen N, Solit DB, Chapman PB.

Oncologist. 2015 Jul;20(7):789-97. doi: 10.1634/theoncologist.2014-0012. Epub 2015 May 8.

Supplemental Content

Loading ...
Support Center